Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Health Care Market Draws Healthy Investment

This article was originally published in PharmAsia News

Executive Summary

Hospital investment and management firm Hua Xia Healthcare Holdings announced that it has put aside funds to acquire 10 private hospitals this year. The company spoke to more than 100 international health care investment organizations in 2007 and found that at least $60 billion capital has been earmarked for China. International Finance Corp., a member of World Bank Group, estimated it invested $700 million in China's hospitals last year. Four health-related enterprises, including Fosun Pharma, received loan support totaling $870 million. Eplanet Ventures plans to complete its second round of fund raising that invests mainly in the health care market in India and China. Domestic investors also see China's market opportunities; Shunde private capitalists have funded an 800 million yuan private hospital that began construction in Guangdong last year. (Click here for more - Chinese Language)

You may also be interested in...



Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel